IJBTT

Health technology assessment of biotechnology medicines with focus on hospital pharmacy

	International Journal of Biotech Trends and Technology (IJBTT)
	© 2020 by IJBTT Journal
	Volume - 10 Issue - 2
	Year of Publication : 2020
	Authors : Svetla Georgieva, PhD
	DOI :  10.14445/22490183/IJBTT-V10I2P603

Citation

MLA Style:Svetla Georgieva, PhD"Health technology assessment of biotechnology medicines with focus on hospital pharmacy" International Journal of Biotech Trends and Technology 10.2 (2020): 16-19.

APA Style:Svetla Georgieva, PhD(2020). Health technology assessment of biotechnology medicines with focus on hospital pharmacy. International Journal of Biotech Trends and Technology, 10(2), 16-19.

Abstract

The study aims to present a general overview of the process of HTA for biotechnology medicines in Bulgaria with special emphasis on hospital practice. It is a regulatory and desktop analysis. We studied the current regulation for HTA of new medicines in Bulgaria for special requirements towards biotechnology medicines for hospital use. A review of the scientific literature on the topic was also undertaken for articles from Bulgarian authors in the field. HTA in the Bulgarian regulatory practice was introduced in 2015 with changes in the Drug Law. The law necessitated that the National Pricing and Reimbursement Council had to perform a HTA of new medicines for the purposes of their inclusion into the Positive Drug List. Our study identified 30 articles, and out of them 17 meeting the inclusion criteria. Those studies could be separated in three therapeutic areas – diabetes, oncology, rare diseases therapy. In the above mentioned areas, newly introduced biotechnology medicines prevail and part of them are originator, others are generic medicines. The process of HTA did not differ between synthetic or biotechnology medicines in Bulgaria. Listing and inclusion into the positive drug list is separated between medicines for ambulatory and hospital settings. Hospital pharmacies should develop rules for internal evaluation of the new technologies from the point of view of the hospital budget.

References

[1] The International Network of Agencies for Health Technology Assessment http://www.inahta.org/ (Accessed March 2020)
[2] "Office of health technology assessment. Development of medical technology?. Opportunity for assessment. Washington DC. US Government printing office. 1976
[3] Banta D. "The development of health technology assessment”, Health Policy 2003; 63:121-13.
[4] Cochrane A. “Effectiveness and efficiency. Abingdon: Burgess & Son," 1972:11.
[5] Bloom BS. "Controlled studies in measuring the efficacy of medical care: a historical perspective". International Journal of Technology Assessment in Health Care 1986;2: 299-310.
[6] Banta H David, Bryan Luce. "Health care technology and its assessment, an international perspective. Oxford: Oxford University Press", 1993:223-366.
[7] Elixhauser A, Luce B, Taylor W, Reblando J. “Health care cost-benefit and cost-effectiveness analysis from 1979 to 1990: a bibliography”. Paper delivered to Academy for Health Services Research and Health Policy Annual Meeting (AHSR), 1992.
[8] Grabowski H., J. Vernon. “Innovation and Structural Change in Pharmaceuticals and Biotechnology". Industrial and Corporate Change, 1994; 3 (2): 435–449, https://doi.org/10.1093/icc/3.2.435
[9] National Peoples Assembly. Medicinal products in human medicine act. In force from 13.04.2007; amend. SG. 43/7 Jun 2016
[10] Ministry Council. Regulation on the conditions, rules and procedures for regulating and registering the prices of medicinal products. State Gazette No 40/2013.
[11] Moorkens E., A. Vulto, I. Huys, P. Dylst, B. Godman, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE 2017; 12(12): e0190147. https://doi.org/10.1371/
[12] Kawalec P., E. Stawowczyk, T. Tesar, J. Skoupa, A. Turcu-Stiolica, et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. Front. Pharmacol. 2017; 8 | https://doi.org/10.3389/fphar.2017.00288
[13] Vassileva M., M. Kamusheva, M. Manova, A. Savova, K. Tachkov, G. Petrova. "Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria." Expert review of pharmacoeconomics & outcomes research, 2019; 19 (6): 1-10. https://doi.org/10.1080/14737167.2019.1592680
[14] Dimitrova M., Petrova G., Tachkov K., Bozhkova M., Kamusheva M., Mitov K., Economic consequences of the vaccination against hepatitis A in the Bulgarian health care settings. Biotechnology and Biotech Eq., 2014; 28 (2): 366-37115.
[15] Dimitrova M., Tachkov K., Petrova G. "Economic consequences of the implementation of national screening program for chronic HCV infection". Expert review of Pharmacoeconomics and Outcomes Research 2019, 1-8. DOI: 10.1080/14737167.2019.1666000
[16] Russel-Szymczyk M., V. Valov, A. Savova, M. Manova. "Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria”. BMC Endocrine Disorders, 2019; 19 (1): 132.
[17] Petrova G., A. Ivanova, M. Czech, V. Valov, W.Wrona, M. Niewada, A. Savova. "Liraglutide vs exenatide in combination with metformin and/or sulfonylurea therapy in type 2 diabetes mellitus therapy in Bulgaria. A model study". 2011; 64 (10): 1507-1514
[18] Ivanova A., G. Petrova, W. Wrona, V. Valov, A. Stoimenova, M. Czech. "Modelling the long term effect of diabetes therapy. An example with liraglutide. Comptes rendus de l’Acad´emie bulgare des Sciences", 2011; 64 (3): 449-456
[19] Tachkov K., K. Mitov, Z. Mitkova, M. Kamusheva, M. Dimitrova, V. Petkova, A. Savova, M. Doneva, D. Tcarukciev, V. Valov, G. Angelova, M. Manova, G. Petrova. "Improved quality of diabetes control reduces complication costs in Bulgaria”. Biotechnology & Biotechnological Equipment 2019; 33 (1): 814-820
[20] Tachkov K., K. Mitov, Y. Koleva, Z. Mitkova, M. Kamusheva, M. Dimitrova, et al. "Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria". PloS one 2020; 15 (5): e0232815
[21] Tachkov K., M. Kamusheva, K. Mitov, M. Doneva, G. Petrova. "Pilot study on the cost of some oncohematology diseases in Bulgaria". Frontiers in public health, 2019; 7: 70. Doi: 10.3389/fpubh.2019.00070
[22] Momekov G., S. Konstantinov, ?. Kamusheva, K. Tachkov, G. Petrova. "Systematic literature review and economic analysis of oncohematilogy diseases therapy". Chapter III. Inquiry research among oncohematology patients in Bulgaria. 2019, Infopharma, Sofia, pages 66-72, ISBN 978-954-92652-6-2
[23] Savova A., M. Kamusheva, S. Georgieva, A. Stoimenova, G. Petrova. "Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria". Biotechnology & Biotechnological Equipment 2013; 27 (1): 3595-3598
[24] Kamusheva M., K. Tachkov, G. Petrova, A. Savova, M. Manova. Orphan medicinal products’ access to the Bulgarian pharmaceutical market–challenges and obstacles. Expert Opinion on Orphan Drugs 2018; 6 (2): 95-104
[25] Kamusheva M., S. Vandeva, K. Mitov, Y. Rusenova, A. Elenkova, S. Zacharieva, et al. “New Epidemiological, Clinical and Economic Data for Patients with Acromegaly in Bulgaria”. Frontiers in Public Health, 2020; 8:147
[26] Petrova G., Tachkov K., Georgieva S., Dimitrova M. "Humanistic and economic aspects of hemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: Prophylactic vs. on-demand treatment,"Biotechnology and Biotechnological Equipment, 2014; 28 (3): 576-582
[27] Tachkov K., Petrova G., "Budget impact analysis of inhibitor hemophilia therapy with bypassing agents". Journal of IMAB - Annual proceeding scientific papers 2019; 25 (2): 2511-2515
[28] Boyadzieva V., Stoilov N., Stoilov R., Tachkov K., Kamusheva M., et al. "Quality of life and cost study of rheumatoid arthritis therapy with biological medicines". Frontiers in Pharmacology, 2018; 9 (18): 794
[29] Kamusheva M., M. Manova, A. Savova, G. Petrova, K. Mitov, et al. “Comparative analysis of legislative requirements about patients` access to biotechnological drugs for rare diseases in Central and Eastern European Countries". Frontiers in pharmacology, 2018; 9: 795
[30] "National council on prices and reimbursement. Price registries". www.ncpr.bg
[31] Ramsey S. et al. “Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force report". Value in health 2005; 8 (5).
[32] Georgieva S., K. Mitov, M. Dimitrova, G. Petrova. "Survival on pharmacotherapy analysis for patients after kidney transplantation". International Journal of Pharmaceutical Sciences Review and Research 2012; 16 (2):30-34

Keywords
health technology assessment, biotechnology medicines, hospital practice, hospital pharmacy